TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women

Mališić, Emina; Janković, Radmila; Brotto, Ksenija; Radulović, Siniša

doi:10.1007/s00404-013-2783-2

Cited by 11 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding is also supported by a meta-analysis with Han Chinese women where the Proline allele was reported to be associated with an increased risk of cervical cancer [ 47 ]. On the contrary, studies in patients with cervical cancer from Serbia and Saudi Arabia did not report an increased risk of the malignancy with the Proline allele [ 22 , 24 ]. Interestingly, the Proline allele was reported to impart a protective effect on cervical cancer [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…The proline allele has also been linked with increased overall survival in Caucasian cervical cancer patients [ 23 ]. On the other hand, the normal homozygous GG genotype, that codes for the arginine allele, has been associated with increased risk of cervical cancer in Serbian and Kyrgyz women [ 24 , 25 ]. Reports of no statistically significant association between TP53 codon 72 polymorphisms with cervical cancer are also available [ 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women

et al. 2021

View full text Add to dashboard Cite

Differential expression of p53 has been reported in cervical cancer, primarily in tumor tissue biopsies. In this study, we examined the association of TP53 codon 47 and codon 72 polymorphisms and serum level expression of p53 in cervical cancer patients (n = 129) and healthy controls (n = 122). We found elevated levels of serum p53 protein levels in cervical cancer patients (p = 0.0442) compared to healthy controls. Moreover, we found higher levels of serum p53 in patients with grade-III tumor (p = 0.001) compared to healthy controls. Examination of SNPs showed TP53 Arg/Pro heterozygosity (adjusted OR = 2.126, 95% CI = 1.181–3.827, p = 0.012), Pro/Pro mutant homozygosity (adjusted OR = 3.564, 95% CI = 1.647–7.713, p = 0.001), along with the combined genotype (Arg/Pro+Pro/Pro) (adjusted OR 2.542, 95% CI = 1.517–4.260, p<0.001) significantly increases the risk of cervical cancer. Expression quantitative trait analysis revealed no significant association with protein expression. Our results represent for the first time the upregulation of serum p53 in cervical cancer in Bangladeshi women and supports the association of TP53 codon 72 polymorphisms with cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The polymorphism has been studied in relation to a wide range of cancers with inconclusive results [ 17 ]. For cervical cancer, the interest has been relatively extensive due to its strong relation with HPV infection [ 22 , 23 ], while studies on vaginal and vulvar cancer have been sparse [ 24 ]. The main focus in the majority of the studies has been the importance of codon 72 on susceptibility to HPV-induced cancer with only some addressing the prognostic value [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Does p53 codon 72 polymorphism have a prognostic value in carcinoma of the vulva and vagina?

et al. 2017

View full text Add to dashboard Cite

Human papilloma virus (HPV) is considered to be responsible for a large part of vaginal and vulvar carcinomas, and the p53 codon 72 polymorphism has been implicated in susceptibility to cancer induced by this virus, but with contradicting results. In this study, we have investigated the prognostic value of the codon 72 polymorphism by real-time PCR (qPCR) in two cohorts of vaginal (n = 66) and vulvar (n = 123) carcinomas. In vaginal carcinoma, arginine homozygous patients were significantly associated with a higher primary cure rate (p = 0.023) but also associated with a higher recurrence rate (p = 0.073), significant at distant locations (p = 0.009). No significant differences were found in overall survival rate (p = 0.499) or cancer-specific survival rate (p = 0.222). A higher frequency of arginine homozygosity was noted in HPV-positive tumors (p = 0.190) in comparison with HPV-negative tumors. In vulvar carcinoma, the genotype homozygous for arginine was significantly associated with a larger tumor size at diagnosis in the entire cohort (p = 0.015) and a lower cancer-specific survival rate (p = 0.024) compared with heterozygous (arginine/proline) in HPV-negative tumors. Our results indicate that the relation between HPV and the p53 codon 72 polymorphism is complex and the significance and mechanisms responsible for this relationship need to be further elucidated.

show abstract

The association between codon72 polymorphism of p53 gene and the risk of endometrial cancer: an updating meta-analysis

Lin

Hou

Huang

et al. 2016

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

TP53 codon 72 polymorphism and risk of cervical carcinoma in Serbian women

Abstract: The results indicate that carriers of Arg allele of codon 72 TP53 gene have an increased risk for development of cervical carcinoma in Serbian women. However, the influence is not statistically significant and requires analysis of larger case-control group.

Cited by 11 publications

References 22 publications

Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women

Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women

Does p53 codon 72 polymorphism have a prognostic value in carcinoma of the vulva and vagina?

The association between codon72 polymorphism of p53 gene and the risk of endometrial cancer: an updating meta-analysis

Contact Info

Product

Resources

About